AKI Subphenotypes Carry Different Risks for Major Adverse Kidney Events
Identification of AKI subphenotypes and their pathogenesis may lead to individualized therapies to prevent adverse kidney events.
Identification of AKI subphenotypes and their pathogenesis may lead to individualized therapies to prevent adverse kidney events.
Benzbromarone, a urate-lowering drug, appeared effective among patients with high serum uric acid levels who had no evidence of gout flares.
Patients with stage 3 chronic kidney disease are at increased risk for contrast-induced acute kidney injury.
Negative association seen between total human resources for health level and all-cause mortality
Currently, there is no approved therapy for calciphylaxis.
Less than half of providers in Denmark say advance care planning is performed well at their workplace
The effects of SGLT2 inhibitors on serum uric acid do not appear to depend on kidney function or diabetes status.
Clinicians have a growing number of options for treating immunoglobulin A nephropathy.
Adverse events rates have been rising over time among patients receiving dialysis, investigators reported.
The relationship between current serum uric acid levels and death followed a U-shape.